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Purpose:  Fibronectin (FN) has been shown to stimulate bone regeneration in animal models. The aim of this study was to 
evaluate the capacity of bovine bone mineral coated with synthetic oligopeptides to enhance bone regeneration in rabbit cal-
varial defects.
Methods:  Oligopeptides including fibrin-binding sequences of FN repeats were synthesized on the basis of primary and ter-
tiary human plasma FN structures. Peptide coated and uncoated bone minerals were implanted into 10 mm calvarial defects 
in New Zealand white rabbits, and the animals were sacrificed at 4 or 8 weeks after surgery. After specimens were prepared, 
histologic examination and histomorphometric analysis were performed.
Results:  At 4 weeks after surgery, the uncoated groups showed a limited amount of osteoid formation at the periphery of the 
defect and the oligopeptide coated groups showed more osteoid formation and new bone formation in the center of the defect 
as well as at the periphery. At 8 weeks, both sites showed increased new bone formation. However, the difference between the 
two sites had reduced.
Conclusions:  Fibrin-binding synthetic oligopeptide derived from FN on deproteinized bovine bone enhanced new bone for-
mation in rabbit calvarial defects at the early healing stage. This result suggests that these oligopeptides can be beneficial in re-
constructing oral and maxillofacial deformities or in regenerating osseous bone defects.
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INTRODUCTION
Various graft materials have been widely used in the recon-
struction of maxillofacial deformities and alveolar bone de-
fects. Ideal grafts should promote the repair by ingrowth of 
new reparative tissue and should allow the delivery of biologi-
cal factors to stimulate bone regeneration. Such substitutes 
should also provide physical strength and protection of the 
underlying structures during healing and should prevent the 
ingrowth of soft tissue. 
Although autogenous bone is regarded as the gold standard 
in osseous reconstruction procedures, donor site morbidity, 
complications, hospital stays, cost, unpredictable graft resorp-
tion, and limited volume availability have been considered 
disadvantages [1-4]. 
Allografts, xenografts, and synthetic materials have been 
shown to promote osseous defect filling in humans [5]. Xeno-
grafts consist of bone mineral from animals or bone-like 
minerals derived from corals or algae [6], and deproteinized 
bovine bone (DBB) has a long history of successful use in fill-
ing in bone defects and maxillary sinus floor grafting [7-12]. As 
proteins in bovine bone have been extracted to avoid immu-
Received:  Jun. 10, 2010;  Accepted:  Aug. 1, 2010
*Correspondence:  Young Ku
Department of Periodontology, Seoul National University School of Dentistry, 28 Yeongeon-dong, Jongno-gu, Seoul 110-749, Korea
E-mail: guy@snu.ac.kr, Tel: +82-2-2072-3182, Fax: +82-2-744-0051Journal of Periodontal
& Implant Science JPIS
Fibrin-binding oligopeptide promotes new bone formation 212
nologic rejection, DBB acts just as an osteoconductive scaf-
fold. However, using an osteoconductive grafting material 
may prolong the healing period, which may cause clinical 
shortcomings. Therefore, reliable bone regeneration requires 
the additional application of suitable bioactive substances to 
the surface of the grafted material in order to enhance osteo-
blast differentiation and proliferation. 
In order to accelerate new bone formation, there have been 
many attempts to combine DBB with proteins or cytokines 
such as recombinant human bone morphogenic protein-2 
and growth factors [13,14]. However, usage of whole natural 
protein imposes many disadvantages, including instability 
from enzymatic degradation, difficulties in obtaining stable 
attachment, nonspecific binding to other types of cells, im-
munogenecity, reduced material availability, relatively high 
cost, and sterilization problems [15,16]. Therefore, synthetic 
oligopeptides, which contain the active binding sequences of 
the natural protein, are regarded to be attractive alternatives, 
due to their ease of synthesis, handling convenience, and the 
reduced immunogenicity.
Fibronectin (FN), a major component of extracellular matrix 
(ECM), mediates a wide variety of cellular interactions with 
the ECM and plays important roles in cell adhesion, migra-
tion, growth, and differentiation [17]. It is a heterodimeric gly-
coprotein and interacts with cells and transmits signals 
through many receptors. FN has a remarkably wide variety 
of functional activities besides binding to cell surfaces through 
integrins. It binds to a number of biologically important mol-
ecules that include heparin, collagen/gelatin, and fibrin, and 
these interactions are mediated by several distinct structural 
and functional domains. 
The FN subunit contains two fibrin binding sites. Among 
these two sites, the major site close to the amino terminus 
serves as a transglutamination site for activated factor XIII, 
crosslinking FN to various other proteins including fibrin, fi-
brinogen, and other FN [18]. The N-terminal site binds first 
due to its higher rate/affinity of fibrin binding, followed by 
the C-terminal site, which may then strengthen the fibrin-
binding interactions of FN. Interaction of FN with fibrin me-
diated by factor XIII transglutaminase is thought to be impor-
tant for cell adhesion or cell migration into fibrin clots. After 
tissue injury, a blood clot formation serves the dual role of 
restoring vascular integrity and serving as a temporary scaf-
fold for the wound healing process. Fibrin and plasma FN, the 
major protein component of blood clots, are vascular essen-
tials to these functions [19]. In blood clotting systems, after fi-
brin deposition, plasma FN-fibrin matrix is covalently cross-
linked, and then it promotes fibroblast adhesion, spreading, 
and migration into the clot [20,21]. Fibroblast migration leads 
to deposition of cellular FN, which serves as a temporary scaf-
fold for further recruitment of cells and granulation tissue 
formation in the wound healing process [22]. Therefore, cross-
linked FN is an absolute requirement for the wound healing 
process. FN can also be cross-linked to collagen, a reaction 
that is potentially important for collagen fibrillogenesis [23].
In this study, we used DBB coated with synthetic oligopep-
tides including fibrin binding sites from amino-terminal FN 
fragments to evaluate the osteopromotive effect of this pep-
tide in rabbit calvarial defects. 
MATERIALS AND METHODS
Preparation of peptide-coated deproteinized bovine bone
Oligopeptides including fibrin-binding sequences of FN 
repeats were designed on the basis of primary and tertiary 
human plasma FN structures (FINC-HUMAN: P02751 [24]). A 
solid-phase peptide synthesizing system was used to prepare 
these oligopeptides. The amino acid sequence was as follows: 
CTSRNRCNDQ. 
Deproteinized cancellous bovine bone particles (OCS-B, NI-
BEC, Seoul, Korea) ranging from 0.2 to 1.0 mm were soaked 
in 3.1 mM synthetic peptide in distilled water. They were kept 
for 18 hours at room temperature after gentle shaking to en-
sure equilibration of the peptide with all exposed surfaces of 
the microporous bone. After freeze drying, the bone particles 
were sterilized by γ-radiation.
Surgical procedures
Twelve New Zealand white male rabbits weighing 2.1 to 2.5 
kg were used. Two circular defects were made in the parietal 
bone of each rabbit. The surgical procedures for this investi-
gation were performed according to recognized techniques 
approved by the Institute of Laboratory Animal Resources, 
Seoul National University. Each animal was premedicated 
according to their weight with an intramuscular injection of 
tiletamine/zolazepam (0.2 mg/kg body weight) and xylazine 
(5 mg/kg body weight). After the surgical site was disinfected 
with betadine, local anesthesia was provided using a 2% lido-
caine solution. An incision was made along the midline of 
the scalp from a point midway between the bases of the ears 
to approximately 5 cm anteriorly through the full thickness 
of the skin. Sharp subperiosteal dissection reflected the peri-
cranium from the outer table of the cranial vault exposing the 
parietal bones. An electric drill with an 8 mm inner diameter 
trephine bur was used to create bilateral full thickness calvar-
ial defects. The defect sizes that resulted ranged from 9.5 to 
10 mm. The peptide coated bone mineral was implanted on 
one side, and uncoated bone mineral was implanted on the 
other side served as a control (Fig. 1). Care was taken to pre-
vent displacement of the bone particles into the other defect Journal of Periodontal
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to prevent a spill-over effect. The pericranium and skin were 
closed with 5-0 chromic gut and 4-0 silk sutures, respectively. 
Six of the animals were euthanized at 4 weeks, and the others 
at 8 weeks. No specimen showed any evidence of infection 
or foreign body reaction, and all wounds healed unevenfully. 
Histologic analysis 
Each animal was euthanized at 4 or 8 weeks. The cranial vault 
was carefully removed from each animal and embedded in 
the media (Technovit 7200, Exakt, Hamburg, Germany) after 
10% neutral buffered formalin treatment with a series of 
ethanol solutions of increasing concentrations. The embed-
ded specimens were mounted on acrylic glass slabs and sec-
tions were cut from the middle of each specimen. The sections 
were grounded and polished to a final thickness of 40 μm. The 
thin sections were stained with hematoxylin-eosin for quan-
tification of the amount of bone regeneration under light 
microscopy. 
Histomorphometric analysis 
Computer-assisted histomorphometric analysis was done 
after conventional microscopic examination. Measurements 
of newly formed bone and graft particles were obtained using 
a software package (TDI Scope Eye, Techsan, Seoul, Korea) 
coupled with a digital camera on a light microscope (BH-2, 
Olympus Optical, Osaka, Japan). The proportion of new bone 
and DBB particles over the entire surface was measured. The 
total perimeter of DBB particles and the portion of the perim-
eter of DBB particles in contact with bone tissue were also 
measured, and the degree (%) of new bone-DBB contact was 
calculated. Two sections were obtained from each biopsy and 
visual fields from each biopsy were measured. 
Statistical analysis
Data were reported as mean ± SD with a significance level 
of P < 0.05. A Mann-Whitney U test was used to compare data 
from histomorphometric analyses. 
RESULTS
Histologic evaluation
At 4 weeks after surgery, in the sites with uncoated bone, the 
defect area was primary occupied by the graft material and 
the connective tissue (Fig. 2A). Few immature osteoid forma-
tions were observed in the central part of the defect and new-
ly formed bone was near the defect border (Figs. 3A and 4A). 
On the other hand, the new bone formation in the site with 
peptide coated bone was more enhanced than that of the 
control sites (Fig. 2B). Most of the specimens showed new 
bone formation extending to the central part of the defect 
(Fig. 3B). Evidence of osteoid formation adjacent to the graft 
Figure 1.  Bilateral calvarial defects were created in parietal bones.
Figure 2.  (A) Histologic view of uncoated bone group after 4 weeks. 
Newly formed bone was found at the periphery of the defect; how-
ever, there was little, if any, new bone formation in the central part 
of the defect. Arrows indicate the margin of the bone defect. (B) 
Histologic view of the peptide coated bone group after 4 weeks. 
New bone formation was obvious and observed in the central part 
of the defect. Arrows indicate the margin of the bone defect (H&E 
staining).
A
B
2 mm
2 mm
Figure 3.  (A) Histologic view of the uncoated bone group at 4 
weeks. Higher magnification of the area marked in Fig. 2A. A very 
limited amount of bone formation around the graft material is not-
ed. (B) Histologic view of the coated bone group at 4 weeks. Higher 
magnification of the area marked in Fig. 2B. New bone formation 
was observed in the central area of the defect (H&E staining).
B A 500 μm 500 μmJournal of Periodontal
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material was found and coalescence of the new bone with 
graft material was observed (Fig. 4B).
At 8 weeks, the amount of the new bone was greater than 
that observed at 4 weeks in both groups. New bone was de-
posited evenly around the graft material and extended to the 
central area of the defects (Fig. 5). The bone mineral was inte-
grated with the new bone and newly formed bones had con-
nected to each other (Fig. 6), especially in the peptide coated 
groups. In higher magnification, multiple bony islands filled 
the central part of the defect (Fig. 7A) and connected each 
other. In the peptide coated group, new bone showed a more 
mature pattern (Fig. 7B). The particles of DBB were easily 
identified. Neither resorption lacunae nor active osteoclasts 
were found in specimens at 4 and 8 weeks.
Histomorphometric evaluation 
The average areas occupied by grafted materials are shown 
in Table 1. There was no significant difference between the 
groups at 4 and 8 weeks (P > 0.05). The average areas occupied 
by new bone was 15.29 ± 1.93% for the control group and 18.84 
 ± 1.75% for the experimental group at 4 weeks. At 8 weeks, the 
average areas were 18.14 ± 2.81% and 19.00 ± 2.08%, respective-
ly (Table 2, Fig. 8). There was a significant difference in the re-
generation areas between the control and experimental group 
at 4 weeks (P < 0.05). At 8 weeks, no statistical difference was 
observed (P > 0.05).
The average bone-DBB contact ratios were 14.50 ± 3.53% for 
the control group and 19.33 ± 3.37% for the experimental group 
at 4 weeks. At 8 weeks, the average contact ratios were 17.36 ±   
3.54% and 19.03 ± 2.79%, respectively (Table 3, Fig. 9). While 
there was a significant difference in the contact ratios between 
control and experimental groups at 4 weeks (P < 0.05), but no 
statistical difference in 8 weeks (P > 0.05).
Table 1. The ratio of the area of the grafted particles to the original 
defect (mean ± SD).
Group 4 weeks (%) 8 weeks (%)
Uncoated bone 33.40 ± 3.19 28.06 ± 6.16
Peptide coated bone 30.37 ± 5.66 27.63 ± 5.49
There was no significant difference between the groups (P > 0.05).
Figure 4.  (A) Higher magnification of Fig. 3A. A very limited 
amount of immature osteoid formation around the graft material 
was noted. (B) Higher magnification of the area marked in Fig 3B. 
Osteoid formation was noted around the graft material (▶). The 
newly generated bone seems well integrated with the graft material 
() (H&E staining).
A B 
▶
Figure 5.  (A) Histologic view of the uncoated bone group after 8 
weeks. New bone formation was noted throughout the defect. Ar-
rows indicate the margin of the bone defect. (B) Histologic view of 
the peptide coated bone group after 8 weeks. New bone formation 
was obvious, and the defect tended to coalesce with new bone. Ar-
rows indicate the margin of the bone defect (H&E staining).
A
B
200 μm 200 μm
2 mm
2 mm
Figure 6.  (A) Histologic view of the uncoated bone group at 8 
weeks. Higher magnification of the area marked in Fig. 5A. New 
bone formation was observed in the central area of the defect. (B) 
Histologic view of the coated bone group at 8 weeks. Higher mag-
nification of the area marked in Fig. 5B. New bone formation was 
observed evenly throughout the defect with highly cellular marrow 
spaces, osteoids, and osteoblsts (H&E staining).
A B
Figure 7.  (A) Higher magnification of Fig. 6A. Multiple bony islands 
fill the central part of the defect (⇒). (B) Higher magnification of 
Fig. 6B. The grafted bone is integrated fully with the new bone (◀) 
and shows a more advanced stage of remodeling and consolidation 
(▶) (H&E staining).
A B
▶
▶
⇒
500 μm 500 μm
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DISCUSSION
In this study, fibrin-binding synthetic oligopeptide derived 
from FN was used to coat the DBB, and the effect was evalu-
ated. Histologic observation showed that no adverse response 
was induced by graft bone, with or without peptide. At 4 weeks 
after surgery, the uncoated bone groups showed evidence of 
osteoid formation near the defect periphery area; however, at 
the center area, osteoid formation was not observed. On the 
other hand, in the coated bone groups, new bone formation 
was observed in the defect center as well as the defect periph-
ery. Among the 4-week models, new bone formation was 
more evident in the coated bone group than in the uncoated 
group. After 8 weeks, new bone formation was observed 
throughout the defect area in both cases. Newly formed bones 
around the DBB were connected to each other and showed a 
more advanced stage of remodeling and maturation. In the 
histomorphometric analysis, the percentage gain of bone re-
generation was calculated as the ratio of the area of newly 
formed bone to that of the original defects. A significant find-
ing in this study is the accelerated formation of new bone 
observed within the experimental groups at 4 weeks. In the 
4-week model, new bond formation in the coated group was 
18.84 ± 1.75% compared with 15.29 ± 1.93% in the uncoated 
group, and there was a statistical difference between the two 
cases (P < 0.05). By 8 weeks, the difference had decreased and 
a statistically significant difference was not observed. The 
new bone ratio in the control group was 18.14 ± 2.81% and in 
the experimental group was 19.00 ± 2.08%. The ratio of the 
contact surface showed a similar pattern. In the 4-week mod-
els, the contact surface ratio was 14.50 ± 3.53% and 19.33 ± 3.37%, 
and in the 8-week models the ratio was 17.36 ± 3.54% and 
19.03 ± 2.79%, for the control and experimental groups, respec-
tively. There was no statistically significant difference in the 
8-week models (P > 0.05). Okazaki et al. [25] found that DBB 
grafted in rabbit calvarial defects showed gradual increases 
in the proportion of newly formed bone at 4 and 8 weeks and 
the proportion of newly formed bone-graft particle contact 
length showed significant increases at 4 weeks and no signifi-
cant changes at 8 weeks, which are consistent with our find-
ing that fibrin-binding synthetic oligopeptide derived from 
FN coated on demineralized bovine bone enhanced new bone 
formation in rabbit calvarial defects, especially in the early 
healing stage. 
FN is a major glycoprotein in the ECM, which binds to in-
Table 2. The ratio of the area of newly formed bone to the original 
defect (mean ± SD).
Group 4 weeks (%) 8 weeks (%)
Uncoated bone 15.29 ± 1.93 18.14 ± 2.81
b)
Peptide coated bone 18.84 ± 1.75
a) 19.00 ± 2.08
a)There was a significant difference between the peptide coated bone group and 
uncoated bone group after 4 weeks (P < 0.05).
b)There was a significant difference between the 4-week and 8-week peptide-
coated mineral groups (P < 0.05).
Figure 8.  Percentages of newly formed bone after implantation for 
different periods using histomorphometric analysis. 
*There was a 
significant difference between the peptide coated bone group and 
uncoated bone group at 4 weeks (P < 0.05). 
**There was a significant 
difference between the 4-week and 8-week uncoated bone group 
(P < 0.05).
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Table 3. The degree of bone-DBB contact (mean ± SD).
Group 4 weeks (%) 8 weeks (%)
Uncoated bone 14.50 ± 3.53 17.36 ± 3.54
Peptide coated bone 19.33 ± 3.37
a) 19.03 ± 2.79
DBB: deproteinized bovine bone.
a)There was a significant difference between the peptide coated bone group and 
uncoated bone group after 4 weeks (P < 0.05).
Figure 9.  Percentages of newly formed bone-deproteinized bovine 
bone contact after implantation for different periods using histo-
morphometric analysis. 
*There was a significant difference between 
the peptide coated bone group and uncoated bone group after 4 
weeks (P < 0.05).
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tegrins and regulates cell survival, growth, motility, and dif-
ferentiation. Many attempts have been made to promote bone 
regeneration using FN; however, the results have been con-
troversial. In 2001, Camargo et al. [26] evaluated the ability of 
FN to augment the regenerative effects of a bovine-derived 
bone in human periodontal defects. They found that a signif-
icant difference between the regenerative treatment modali-
ties could not be demonstrated. On the other hand, Lekovic 
et al. [27] used bovine porous bone mineral in combination 
with an autologous fibrinogen/FN system in the treatment 
of intrabony periodontal defects in humans. They found that 
the autologous fibrin/fibrinogen system used in combination 
with bovine porous bone mineral has some effect in promot-
ing probing depth reduction, clinical attachment gain, and 
defect fill when employed as regenerative therapy for intraos-
seous lesions in humans. Di Bella et al. [28] reported that sur-
face treatment with FN promotes bone formation within the 
polylactic acid scaffold in a critical-sized defect rabbit model 
with or without autologous adipose-derived mesenchymal 
stem cells in combination. In 2008, Schonmeyr et al. [29] 
found in vitro attachment and proliferation of bone-forming 
cells on hydroxyapatite is significantly increased by pretreat-
ment with FN/fetal calf serum, but this difference is less pro-
found and not significant in vivo. This controversy could be 
due to the common shortcomings of whole protein usage, 
including instability to enzymatic degradation, unexpected 
effects of other domains, nonspecific binding to other types 
of cells, difficulty in obtaining stable attachment, and even 
integrin blocking effects [15,16]. Therefore, small synthetic 
peptides with active binding sequences of natural proteins 
have been proposed as alternatives. In our previous study, fi-
brin-binding synthetic oligopeptide showed marked enhance-
ment in periodontal ligament cell proliferation, attachment, 
and mineralization [30]. These results can be compared with 
those obtained from previous studies conducted by other re-
searchers using similar animal models. Augmentation of the 
maxillary sinus using DBB with or without recombinant hu-
man bone morphogenic protein (rhBMP)-7 was performed 
by Terhyeden et al. [31] using DBB in minipigs. A significant 
increase in bone formation was found (38.6-80.0%) when rh-
BMP-7 was added to the graft. In 2007, Park et al. [32] demon-
strated that the use of DBB with a synthetic rhBMP-7 seems to 
be a more beneficial material for bone regeneration in the 
early healing period. They detected a significant difference 
in the percentage of new bone formation between peptide-
coated group and peptide-uncoated group: 6.60 ± 0.89% and 
23.72 ± 1.73% at 2 weeks, 34.77 ± 3.31% and 42.27 ± 2.35% at 4 
weeks, respectively. On the contrary, Gordjestani et al. [33] in-
vestigated the influence of osteopontin on bone repair in 
rabbit calvarial defects. There were no statistically significant 
differences in total bone formation between defects filled with 
osteopontin-hydroxyapatite and those with hydroxyapatite 
only. The differences identified in the amount of reparative 
tissue seen in our study and previous other studies can be 
explained by the biomaterials used for each study. Compared 
with other studies, our study observed a lower percentage of 
new bone gain, but fibrin-binding synthetic oligopeptide de-
rived from FN might have some effect as a DBB coating ma-
terial, especially in the early bone healing stage. 
The creation of nonunions in animals within the calvaria 
and mandible was size dependent. A critical size defect (CSD) 
was defined as the smallest size intraosseous wound in a par-
ticular bone and species of animal that will not heal sponta-
neously during the lifetime of the animal [34]. It was known 
that the size of a CSD was dependent on the breed and age 
of the experimental animal model used as well as the loca-
tion of the defect. Frame [35] described the healing of 15-mm 
diameter defects in the calvaria of rabbits. After 24 and 36 
weeks, the 15 mm diameter defects had healed by the forma-
tion of fibrous connective tissue. Also, Hollinger and Klein-
schmidt [36] confirmed that untreated 15-mm cranial defects 
created in New Zealand white rabbits showed less than 10% 
bone regeneration after 48 weeks. However, Ascherman et al. 
[37] used 10-mm diameter defects as a CSD in their study of 
the 6-month histology of a quick-setting hydroxyapatite ce-
ment, with and without absorbable plates. In 2007, Pripat-
nanont et al. [38] used a bicortical 10 × 10 mm skull defect mod-
el in their study examining the osteoconductive ability of 3 
bovine hydroxyapatites. After 8 weeks, the controls showed 
bone formation around the marginal bone, showing projec-
tion in a centripetal direction. In the upper and lower parts of 
the defect, woven bone was projected from the edges of the 
defects, whereas in the central part, only fibrous connective 
tissue occupied the defect. 
Resorption and complete remodeling into new bone are 
the ideal outcomes of a grafting material. In this study, the 
ratio of grafted DBB did not change much according to the 
type of grafted material or healing period. The resorption of 
DBB has been a controversial subject in many studies. McAl-
lister et al. [39] detected a decrease in the percentage of DBB, 
from 19 ± 14% to 6 ± 3% over a time period of 7.5-18 months in 
a chimpanzee study. Klinge et al. [40] found that DBB parti-
cles in defects of rabbit calvarial skulls had almost completely 
disappeared after 14 weeks of healing, as the effect of multi-
nucleated cells. Based on these results, they suggested that 
DBB had been resorbed and replaced by vital bone. On the 
other hand, Schlegel [41] could identify DBB particles after a 
healing period of up to 7 years and Skoglund et al. [42] also 
suggested that DBB particles were slowly degraded and re-
mained 44 months after augmentation of a maxillary alveolar Journal of Periodontal
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ridge. Yildrim et al. [43] suggested that such a difference in 
bony healing of DBB is mainly influenced by the healing re-
sponse of the individual patient and is less dependent on the 
healing time of the augmentation material. From a biologic   
point of view, resorption requires adhesion molecules (argi-
nine-glycine-aspartic acid [RGD] sequence) for the attach-
ment of osteoclastic cells to plasma and ECM, including FN, 
fibrinogen, vitronectin, type I collagen, osteopontin, and bone 
sialoprotein [44]. As DBB is free of proteins, osteoclastic re-
sorption can probably not occur. However, Schwartz et al. [12] 
observed transforming growth factor-β and BMP-2 in DBB 
particles, which might explain the lacunae found in some DBB 
particles. Rooney et al. [45] interpreted possible signs of re-
sorption as evidence of osteoclastic resorption mediated by 
later surface adsorption of proteins containing RGD sequenc-
es, such as FN or fibrinogen. In this study, we used fibrin 
binding sequences of FN as DBB coating material; therefore, 
the RGD sequence of FN is not included and results of the 
initial healing stage, that is, post-surgery 2 weeks, were not in-
cluded. Further investigation about DBB resorption is needed. 
In this study, the peptide mentioned above was used to coat 
DBB, and the effects on bone regeneration were evaluated. 
The study was done at 4-week and 8-week periods to evalu-
ate bone formation in the early and late healing period. His-
tologic observation showed that no adverse response was in-
duced by the graft, with or without peptide. The amount of 
new bone at sites with peptide-coated bone mineral was 
greater than at sites with uncoated bone. The new bone was 
deposited evenly around the graft material, and the bone min-
eral was integrated fully with the new bone in experimental 
sites. By histomorphometric analysis, the percentage gain in 
bone regeneration was calculated as the ratio of the area of 
newly formed bone to the area of the original defect. A sig-
nificant finding in this study is the accelerated formation of 
new bone observed at experimental sites compared to con-
trol sites at the early healing stage. However, more studies are 
required to determine the quantity of peptide suitable for 
optimal bone regeneration and DBB coating method.
These results suggest that the formation of new bone and 
the normal healing process occur more rapidly when synthet-
ic oligopeptide is used.
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